Can serum HBV-DNA be used as a primary end point to assess efficacy of new treatments for chronic hepatitis B?

Authors

  • Alfredo Alberti M.D

    Corresponding author
    1. Department of Clinical and Experimental Medicine, University of Padova, Venetian Institute of Molecular Medicine, Padova, Italy
    • Department of Clinical and Experimental Medicine, University of Padova, Via Giustiniani 2, 35121 Padova, Italy. fax: (39) 049-8211826
    Search for more papers by this author

No abstract is available for this article.

Ancillary